



Receipt
#5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Michael W. LEVITEN.

Group Art Unit: 1645

Serial No. 09/922,960

**REQUEST FOR CORRECTED
FILING RECEIPT**

Filed: August 3, 2001

Title: Transgenic Mice Containing Ubiquitin
Protein Ligase E3 Gene Disruptions

October 9, 2001

Commissioner of Patents
Washington, D.C. 20231
Attention: Filing Receipt Correction

Sir:

1. Enclosed is a copy of the official filing receipt from the PTO in the above application for which issuance of a corrected filing receipt is respectfully requested.

2. There is an error with respect to the following data:

Error in:

Correct data:

- a. ☐ Applicant's name:
- b. ☐ Applicant's address:
- c. ☐ Title:
- d. ☒ Other:


First listed priority claim (60/215,397) should be deleted.

3. ☐ The correction is not due to any error by applicant and no fee is due.


4. ☒ The Commissioner is hereby authorized to charge our Deposit Account No. 50-1271, Order #R-441, for any fee which may be due, for which purpose this Request is filed in duplicate.

DELTAGEN, INC.


740 Bay Road
Redwood City, CA 94063
Tel: (650) 569-5174
Fax: (650) 569-5574


for Jane K. Babin, Reg. No. 47,224

I certify that this paper is being deposited with the U.S. Postal Service as first class mail in an envelope with postage prepaid, addressed to Commissioner for Patents, Washington, D.C. 20231, Attn: FILING RECEIPT CORRECTION on October 9, 2001


Gayle D. Peterson

BEST AVAILABLE COPY




UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/922,960	08/03/2001	1645	0.00	R-441	2	29	14

CONFIRMATION NO. 9830

FILING RECEIPT



OC000000006513851

DELTAGEN, INC.
1003 Hamilton Avenue
Menlo Park, CA 94025

Date Mailed: 09/05/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Michael W. Leviten, Palo Alto, CA;

Domestic Priority data as claimed by applicant

THIS APPLN CLAIMS BENEFIT OF 60/215,397 06/29/2000
AND CLAIMS BENEFIT OF 60/223,461 08/07/2000
AND CLAIMS BENEFIT OF 60/223,385 08/07/2000

Foreign Applications

If Required, Foreign Filing License Granted 09/05/2001

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

Transgenic mice containing ubiquitin protein ligase E3 gene disruptions

Preliminary Class

435

BEST AVAILABLE COPY

Data entry by : PRASASOUK, NOUSALY

Team : OIPE

Date: 09/05/2001



BEST AVAILABLE COPY

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 500 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
 Office of Initial Patent Examination
 Customer Service Center
 Washington, DC 20231

BEST AVAILABLE COPY